Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
33.33
-0.38 (-1.13%)
At close: Apr 28, 2026, 4:00 PM EDT
34.38
+1.05 (3.15%)
After-hours: Apr 28, 2026, 6:30 PM EDT
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Stoke Therapeutics stock have an average target of 39.2, with a low estimate of 25 and a high estimate of 60. The average target predicts an increase of 17.61% from the current stock price of 33.33.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 20, 2026.
Analyst Ratings
The average analyst rating for Stoke Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 8 | 7 | 7 | 7 |
| Buy | 2 | 1 | 1 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $36 → $60 | Strong Buy | Maintains | $36 → $60 | +80.02% | Mar 20, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $39 | Strong Buy | Reiterates | $39 | +17.01% | Mar 19, 2026 |
| Wedbush | Wedbush | Buy Maintains $36 → $38 | Buy | Maintains | $36 → $38 | +14.01% | Mar 18, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $35 | Strong Buy | Maintains | $35 | +5.01% | Mar 18, 2026 |
| Wedbush | Wedbush | Buy Maintains $36 → $38 | Buy | Maintains | $36 → $38 | +14.01% | Mar 17, 2026 |
Financial Forecast
Revenue This Year
33.19M
from 184.42M
Decreased by -82.00%
Revenue Next Year
58.91M
from 33.19M
Increased by 77.49%
EPS This Year
-3.41
from -0.12
EPS Next Year
-3.10
from -3.41
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 73.5M | 110.3M | ||||||
| Avg | 33.2M | 58.9M | ||||||
| Low | 11.7M | 19.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -60.1% | 232.2% | ||||||
| Avg | -82.0% | 77.5% | ||||||
| Low | -93.7% | -40.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.61 | -2.14 | ||||||
| Avg | -3.41 | -3.10 | ||||||
| Low | -3.79 | -3.71 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.